Label: nystatin- nystatin powder
-
Contains inactivated NDC Code(s)
NDC Code(s): 49884-900-18, 49884-900-98 - Packager: Par Pharmaceutical Inc.
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
Drug Label Information
Updated August 10, 2007
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
- N/A - Section Title Not Found In Database
- DESCRIPTION
-
CLINICAL PHARMACOLOGY
Microbiology
Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes.
Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida (C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed.
Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
-
PRECAUTIONS
General
Nystatin topical powder should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections.
If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.
-
INFORMATION FOR THE PATIENT
Patients using this topical powder should receive the following information and instructions:
- The patient should be instructed to use this powder as directed (including the replacement of missed doses). This topical powder is not for any disorder other than that for which it is prescribed.
- Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.
- If symptoms of irritation develop, the patient should be advised to notify the physician promptly.
Laboratory Tests
If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility.
Pregnancy: Teratogenic Effects
Category C. Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin topical preparations should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.
- ADVERSE REACTIONS
-
DOSAGE AND ADMINISTRATION
Very moist lesions are best treated with the topical dusting powder.
Adults and Pediatric Patients (Neonates and Older):
Apply to candidal lesions two (2) or three (3) times daily until healing is complete. For fungal infection of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.
-
HOW SUPPLIED
100,000 units nystatin per gram in 15 g (NDC 49884-900-18) plastic squeeze bottles.
100,000 units nystatin per gram in 56.7 g (NDC 44894-900-98) plastic squeeze bottles.
-
INGREDIENTS AND APPEARANCE
NYSTATIN
nystatin powderProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:49884-900 Route of Administration TOPICAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Nystatin (UNII: BDF1O1C72E) (Nystatin - UNII:BDF1O1C72E) 100000 in 1 g Inactive Ingredients Ingredient Name Strength talc (UNII: 7SEV7J4R1U) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:49884-900-98 56.7 g in 1 BOTTLE, PLASTIC 2 NDC:49884-900-18 15 g in 1 BOTTLE, PLASTIC Labeler - Par Pharmaceutical Inc.